Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
THE man charged with clawing Sri Lanka out of bankruptcy said he had warned about economic calamity years before it hit - and was pressed into retirement for his troubles.
Central bank chief Nandalal Weerasinghe was asked to return to the island nation last year to help steer it through a financial collapse that triggered months of food shortages, petrol queues and nightly blackouts.
The 63-year-old said his mandate coincides with Sri Lanka's one final opportunity to rescue itself from a cycle of economic shocks that stretches back decades.
"There's no excuse this time, no second chance, we have to get it right this time," he said at his Colombo office last week.
"This is where I think crisis is an opportunity."
Weerasinghe was the Central Bank of Sri Lanka's number two when Gotabaya Rajapaksa was elected president in 2019 on populist promises of generous tax cuts.
Government debt soared as Rajapaksa pursued an unorthodox policy of printing exorbitant amounts of money while holding down exchange and interest rates to spur growth.
"As the senior deputy governor, I always raised concerns," Weerasinghe said.
But with Rajapaksa's administration steamrolling objections from him and other senior central bankers, Weerasinghe said he felt he had no option but to take early retirement.
"Obviously, I saw if those policies continued in that way... we'll end up in a situation that I said at that time was exactly what happened," he added.
Weerasinghe left for a quiet life in Australia, spending time with his children and hitting the golf course five days a week, when Rajapaksa asked him to return and helm the central bank.
Sri Lanka’s currency was in freefall and the government was days from defaulting on its $46 billion (£36bn) foreign debt.
By July, Rajapaksa had fled the country after months of protests demanding his resignation for mismanaging the crisis.
Rajapaksa's successor, Ranil Wickremesinghe, has sought to repair the nation's finances through a $2.9bn (£2.26bn) International Monetary Fund bailout.
The rescue package commits Sri Lanka to an austerity regime of steep tax hikes and an end to generous consumer utility subsidies, both of which have proven deeply unpopular.
Its passage was reportedly held up for months when China - Sri Lanka's largest bilateral creditor - resisted agreeing to a haircut on its loans.
Chinese debt has been controversial politically, with Rajapaksa and his elder brother Mahinda - himself a former president - accused of taking Beijing's money to finance costly vanity projects.
Weerasinghe said the delays to the IMF package were understandable because Beijing was a relatively "new player" to bilateral lending.
"China is fully on board and agreed to support Sri Lanka and help Sri Lanka to come out of this crisis," he said.
Sri Lanka had already gone to the IMF cap in hand 16 times before last year, but failed to stick with agreed-upon reforms, giving it a serious credibility gap.
Weerasinghe said the country had two choices this time around: if it sticks to its current IMF programme, its economy would return to normal within "two to four years".
If it did not, Sri Lanka would no longer be indulged if it fell off the wagon and returned to its spendthrift ways at the first sign of stability, he warned.
"This time, the 17th time with the IMF, is different," he said.
"If you are trying to go back to another programme, that will be most difficult, and I think that will be the end of the story."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.